Hormone monitoring has traditionally relied on blood tests that provide a single momentary reading, requiring lab visits and specialized equipment. Level Zero Health, a healthtech startup based in London and San Francisco, is working on a different approach. The company is developing DNA-based sensors designed to continuously track hormone levels in real-time, addressing long-standing challenges in hormone analysis. With the latest funding injection, it aims to refine this technology and expand its research efforts. The growing interest in remote health monitoring suggests a wider shift toward personalized and accessible healthcare solutions.
In previous funding rounds, many healthtech startups struggled due to economic uncertainty and investor hesitancy. Despite this, Level Zero Health managed to attract significant backing, highlighting the demand for innovation in hormone monitoring. While other companies have attempted to develop non-invasive hormone tracking solutions, few have advanced as quickly in validation and clinical range testing. The company’s approach, which integrates biosensors with remote monitoring, differs from existing methods that typically rely on intermittent lab-based hormone assessments.
How does Level Zero Health’s technology work?
The company has created a wearable patch that continuously monitors hormone levels through interstitial fluid, rather than requiring blood samples. This method offers a less invasive alternative to traditional hormone tests, which depend on periodic lab visits. By using nanotechnology and biochemistry, the device provides real-time hormonal data, enabling users to track hormone fluctuations more effectively. The goal is to enhance various healthcare applications, including fertility treatments, menopause management, and testosterone therapy.
Level Zero Health has validated its biosensors across 98% of the human clinical range within a short period. The company sees its technology as a step toward making hormone diagnostics more accessible and informative. With clinical experts backing the initiative, the company’s device could change how hormone-related conditions are monitored and treated.
Who is investing in Level Zero Health?
European VC firm Redalpine led the £5.5M pre-seed investment round, with participation from HAX (SOSV), Entrepreneur First, and other investors. Individual backers include experts in fertility and endocrinology, such as Aaron Styer from Harvard Medical School and Joshua Klein from Icahn School of Medicine. These investors bring industry experience that could support the company’s market strategy and clinical expansion.
Philip Kneis, an investor at Redalpine, commented on the investment:
“We did it for blood pressure and will do it again for hormones. Continuous hormone measurement is one of the holy grails of diagnostics, and as fundamental science transitions to engineering, we couldn’t be more excited to back Level Zero Health in their mission to transform hormone tracking with their novel biosensor.”
The funding will be allocated to product development, clinical research, and hiring staff in the UK and US. While the company is starting with B2B applications, it is also considering expansion into consumer markets and pharmaceutical collaborations.
Level Zero Health has also established a clinical advisory board that includes medical professionals from leading institutions. They aim to guide the company’s research efforts and validate the effectiveness of its biosensors in real-world applications.
Continuous hormone monitoring has been a longstanding challenge for the medical industry, with traditional methods often proving inconvenient for patients. Level Zero Health’s non-invasive biosensor technology could offer an alternative that simplifies hormone tracking. However, as with any emerging healthtech solution, regulatory approvals and clinical trials will play a critical role in determining its widespread adoption. If successful, the technology may influence how hormone-related disorders are managed, potentially reducing dependence on laboratory-based diagnostics.
